In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia reports quality variance in public hospitals:

This article was originally published in Clinica

Executive Summary

This month, Australia released a five-year report on the state of the country's public hospitals. During this period, the government invested more than Aus$31bn (US$21.4bn) in public hospitals, but the report shows that some areas of hospital performance have regressed. For example, in 2002-03 people waited longer in emergency departments and for elective surgery than the recommended time, compared to 1998-99. Quality of service also varies according to state. Tasmanians who require a hip replacement have longer waiting times than residents of other states or territories, the report says. However, despite the increase of waiting lists, 85% of patients are treated within the appropriate time, says the ministry of health. The report also shows that the number of available public hospital beds is decreasing, which the government claims is indicative of the importance of a viable private hospital sector.

You may also be interested in...



Notified Body Expert Akra Calls For Special Taskforce Measures To Oversee New COVID-19 Products

With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.

India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up

Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.

Dissecting The Impact: Chi-Med Details Coronavirus Experience

CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical. 

Topics

UsernamePublicRestriction

Register

MT058929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel